A Bayesian network meta-analysis comparing four oral JAK inhibitors-upadacitinib, abrocitinib, baricitinib, and ivarmacitinib-in moderate-to-severe atopic dermatitis has found that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results